13982-84-8 Usage
Uses
Used in Pharmaceutical Industry:
4-Methyl-8-quinoxalinesulfonyl Chloride is used as a synthetic intermediate for the preparation of 8-mercaptoquinoline, which is an important compound in the pharmaceutical industry. The synthesis of 8-mercaptoquinoline involves the use of this quinoxalinesulfonyl compound as a key building block, allowing for the creation of various pharmaceutical agents with potential therapeutic applications.
Used in Chemical Analysis:
In addition to its role in the pharmaceutical industry, 4-Methyl-8-quinoxalinesulfonyl Chloride is also used in the field of chemical analysis. It serves as a reagent for the preparation of 8-mercaptoquinoline, which can be further utilized in the analysis and identification of various compounds. This application highlights the versatility of 4-Methyl-8-quinoxalinesulfonyl Chloride in both synthetic and analytical chemistry.
Check Digit Verification of cas no
The CAS Registry Mumber 13982-84-8 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 1,3,9,8 and 2 respectively; the second part has 2 digits, 8 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 13982-84:
(7*1)+(6*3)+(5*9)+(4*8)+(3*2)+(2*8)+(1*4)=128
128 % 10 = 8
So 13982-84-8 is a valid CAS Registry Number.
13982-84-8Relevant academic research and scientific papers
COMPOUNDS FOR REGULATING FAK AND/OR SRC PATHWAYS
-
Page/Page column 88, (2015/03/28)
The present application provides novel optionally substituted fused pyridine and pyrimidine bicyclic compounds and pharmaceutically acceptable salts thereof. Also provided are methods for preparing these compounds. These compounds are useful in co-regulating FAK and/or Src activity by administering a therapeutically effective amount of one or more of the compounds to a subject. By doing so, these compounds are effective in treating conditions associated with the dysregulation of the FAK and/or Src pathway. Advantageously, these compounds perform as dual FAK and/or Src inhibitors. A variety of conditions can be treated using these compounds and include diseases which are characterized by inflammation or abnormal cellular proliferation. In one embodiment, the disease is cancer.
